Pablo Rengifo-Moreno, MD
Interventional Cardiology · Fort Lauderdale, FLNPI 1356500854
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Edwards Lifesciences at 32.0% of the total. 2025 is the largest year on record at $19,016, 4.6 times the $4,106 reported in 2019. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 584 payments — averaging $104.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$19K
- Medtronic$13K
- Boston Scientific$13K
- Abbott$6K
- Abiomed$4K
- Inari Medical, Inc.$793
- plus $4K from 32 others
Across 45 payments — averaging $4621.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cathworks, Inc.$188K
- Abbott$20K
- Abiomed$278
What the payments were for
- Consulting fees$8,03013%
- Speaking & faculty fees$5,0358%
- Grants$5,3339%
- Travel & lodging$16,91628%
- Food & beverage$25,34642%
- Education$1440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 85 | $19,447 |
| Medtronic(2 entities) | 147 | $13,103 |
| Boston Scientific | 78 | $12,914 |
| Abbott | 65 | $6,236 |
| Abiomed | 42 | $4,178 |
| Inari Medical, Inc. | 27 | $793 |
| Shockwave Medical, Inc | 11 | $664 |
| Amgen | 30 | $566 |
| Cathworks, Inc. | 2 | $432 |
| Penumbra, Inc. | 19 | $375 |
| W. L. Gore & Associates, Inc. | 3 | $298 |
| Cardiac Dimensions, Inc. | 2 | $214 |
| E.r. Squibb & Sons, L.L.C. | 12 | $211 |
| Angiodynamics, Inc. | 3 | $201 |
| Cardiovascular Systems Inc. | 9 | $151 |
| Cleerly, Inc. | 1 | $105 |
| AstraZeneca(2 entities) | 7 | $97 |
| Amarin Pharma, Inc. | 2 | $91 |
| Livanova USA, Inc. | 1 | $77 |
| Pfizer | 5 | $76 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $65 |
| Johnson & Johnson | 4 | $64 |
| Stryker | 2 | $60 |
| Philips North America LLC | 2 | $55 |
| Elutia, Inc. | 2 | $53 |
| Biotronik Inc. | 2 | $39 |
| Cardiva Medical, Inc. | 2 | $38 |
| Biosense Webster, Inc. | 1 | $30 |
| Cordis US CORP. | 1 | $26 |
| Novartis | 2 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Haemonetics Corporation | 1 | $20 |
| Silk Road Medical, Inc. | 1 | $17 |
| Teleflex LLC | 1 | $15 |
| ZOLL Circulation Inc | 1 | $14 |
| Bayer | 1 | $13 |
| Cardinal Health 200 LLC | 1 | $13 |
| Procyrion, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL BALLOONS$7,500
- Edwards SAPIEN 3 Transcatheter Heart Valve$5,652
- CoreValve Evolut$5,443
- Impella$3,243
- RESOLUTE ONYX$1,866
- COREVALVE EVOLUT R$1,493
- AVVIGO Guidance System$1,482
- EVOQUE$1,261
- PASCAL$1,047
- SAPIEN 3 Ultra RESILIA$889
- AMPLATZER Occluders$871
- FFRangio$712
- MitraClip System$613
- PORTICO$593
- Mitra Clip system$462
- FLOWTRIEVER CATHETER, S$409
- GENERAL - THERAPIES$363
- GORE CARDIOFORM Septal Occluder$290
- MitraClip$285
- Vascular Lithotripsy$279
How this compares
$60,803 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 206 | $147,212 |
| EntrestoSacubitril/Valsartan | 61 | $65,380 |
| Repatha SureclickEvolocumab | 79 | $47,015 |
| FarxigaDapagliflozin Propanediol | 29 | $31,116 |
| JardianceEmpagliflozin | 44 | $28,060 |
| BrilintaTicagrelor | 44 | $23,804 |
| XareltoRivaroxaban | 12 | $11,935 |
| Ranolazine ErRanolazine | 84 | $5,003 |
| Metoprolol Succinate | 424 | $4,996 |
| Atorvastatin Calcium | 277 | $3,614 |
| VascepaIcosapent Ethyl | 11 | $2,082 |
| Rosuvastatin Calcium | 157 | $1,385 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 171 | $1,282 |
| Losartan Potassium | 152 | $1,272 |
| Carvedilol | 126 | $1,051 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $76 | $147,212206 claims |
| NovartisEntresto | $24 | $65,38061 claims |
| AstraZenecaFarxiga, Brilinta | $97 | $54,92073 claims |
| Johnson & JohnsonXarelto | $64 | $11,93512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Fort Lauderdale
- Edgardo dos SantosFort Lauderdale$93K
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.